This page shows the latest 2seventy bio news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb (BMS) and 2seventy bio – a spin-out of bluebird bio – have announced positive phase 3 trial top-line results for Abecma (idecabtagene vicleucel) as a treatment for relapsed ... Steve Bernstein, chief medical officer, 2seventy bio,
2021. The decision made by BMS and 2seventy bio reinforces that the companies’ hopes are pinned on Abecma, as the drug has been in high demand. ... Both companies said they anticipated between $250m and $300m in Abecma sales in 2021, with profits to be
2seventy bio gets the company’s immune-oncology cell therapies products, while bluebird bio will continue its work on severe genetic diseases. ... As announced earlier this year, Cambridge, Massachusetts-based bluebird bio has spun off its oncology
bluebird bio has announced the filing by 2seventy bio of an updated Registration Statement with the US Securities and Exchange Commission (SEC). ... This reflects bluebird bio’s plans for a spin-off of its oncology programmes and portfolio into
The company has filled its coffers with $75m in new funding and hired new leaders to support its split into two separate companies, bluebird bio and 2seventy bio. ... In October, the company will split into two independent, publicly traded companies,
This is not the first such incident for bluebird bio’s gene therapies. ... The company will continue its planned split into two independent, publicly traded companies – bluebird bio and 2seventy bio – by the end of 2021.
More from news
Approximately 6 fully matching, plus 3 partially matching documents found.
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...